APC Factor V Resistance |
| 1. |
Dahlbäck B et al. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anti-coagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci 90, 1004-1008. (1993) |
| 2. |
Svensson P J and Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330, 517-522 (1994). |
| 3. |
Bertina R M et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994). |
| 4. |
Voorberg J et al. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 343, 1535-1536 (1994). |
| 5. |
Greengard J S et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343, 1361-1362 (1994). |
| 6. |
Williamson D et al. Factor V Cambridge: A new mutation (Arg306->Thr) associated with resistance to activated protein C. Blood 91, 1140-1144 (1998). |
| 7. |
Jorquera J I et al. Modified test for activated protein C resistance. Lancet 344, 1162-1163 (1994). |
| 8. |
Trossaërt M et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 344, 1709 (1994). |
| 9. |
Svensson PJ et al. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 77, 332-335 (1997). |
| 10. |
Freyburger G et al. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients. Thromb Haemost 78, 1360-1365 (1997). |
| 11. |
Hall C et al. Evaluation of a modified APTT-based method for determination of APC resistance in plasma from patients on heparin or oral anticoagulant therapy. Thromb Res 89, 203-209 (1998). |
| 12. |
National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3. |
| 13. |
Freyburger G et al. Response to activated protein C upon storage of whole blood and plasma. Thromb Res 93, 89-95 (1999). |
| 14. |
National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A3; vol. 11 No. 23. |
| 15. |
National Committee for Clinical Laboratory Standards. EP5-T2. User evaluation of clinical chemistry devises. |
| 16. |
Hirsh J. Venous Thromboembolism. In: Hoffman R et al (eds) Hematology, Basic Principles and Practice. Churchill Livingstone, 1465-1484 (1991). |
| 17. |
Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Tuddenham EGD, Bloom AL, Forbes CD, Thomas DP (eds) Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1327-1333 (1994). |
| 18. |
Thomas DP. Pathogenesis of venous thrombosis. In: Tuddenham EGD, Bloom AL, Forbes CD, Thomas DP (eds) Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1335- 1347 (1994). |
| 19. |
Heijboer H, Brandjes D, Büller HR et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein-thrombosis. New Eng J Med 323, 1512-1516 (1991). |
| 20. |
Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation. Thromb Haemost 68, 7-13 (1992). |
| 21. |
Pabinger I, Brücker S, Kyrle PA et al. Hereditary deficiency of antithrombin, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibr 3, 547-553 (1992). |
| 22a. |
Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 1. Thromb Haemost 76, 651-662 (1996). |
| 22b. |
Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 2. Thromb Haemost 76, 824-834 (1996). |
| 23. |
Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci 90, 1004-1008 (1993). |
| 24. |
Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82, 1989-1993 (1993). |
| 25. |
Koster T, Rosendaal F, de Ronde H et al. Venous Thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342, 1503-1506 (1993). |
| 26. |
Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med 330, 517-522 (1994). |
| 27. |
Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Letters to the Editor. Blood 94, 2008 -2009 (1994). |
| 28. |
Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to Activated Protein C. Nature 369, 64-67 (1994). |
| 29. |
Voorberg J, Roelse J, Koopman R et al. Association of idiopathic venous thromboembolism with single point- mutation at Arg506 of Factor V. Lancet 343, 1535-1536 (1994). |
| 30. |
Zöller B, Dahlbäck B. Linkage Between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343, 1536-1538 (1994). |
| 31. |
Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest, 94, 2521-2524 (1994). |
| 32. |
Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 30, 10363-10370 (1991). |
| 33. |
Mosher DF. Blood coagulation and fibrinolysis: an overview. Clin Cardiol 13, VI 5-11 (1990). |
| 34. |
Morrissey JH. Tissue factor.In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 101-118 (1995). |
| 35. |
Saito H, Kojima T. Factor XII, prekallikrein, and highmolecular-weight kininogen. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 269-285 (1995). |
| 36. |
Degen SJF. Prothrombin. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 75-100 (1995). |
| 37. |
Ortel TL, Kane WH. Factor V. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 119-146 (1995). |
| 38. |
Tuddenham EGD. Factor VIII. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 167-195 (1995). |
| 39. |
Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 57, 915-956 (1988). |
| 40. |
Olson ST. Björk I. Regulation of thrombin by antithrombin and heparin cofactor II.
In: Berliner LJ (ed) Thrombin: structure and function. New York: Plenum Press 159-217, (1992). |
| 41. |
Jaffe AE. Endothelial cell structure and function. In: Hoffman R et al (eds) Hematology, basic principles and practice. Churchill Livingstone, 1198-1212 (1991). |
| 42. |
Dahlbäck B, Stenflo J. A natural anticoagulant pathway: proteins C,S, C4b-binding protein and thrombomodulin. In: Haemostasis and Thrombosis 3rd ed. A L Bloom, C D Forbes, D P Thomas, E G D Tuddenham (eds). Churchill Livingstone, 671-697 (1994). |
| 43. |
Dahlbäck B. The protein C anticoagulant system: inherited defects as a basis for venous thrombosis. Thromb Res 77, 1-43 (1995). |
| 44. |
Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 269, 18735-18738 (1994). |
| 45. |
Váradi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. - Letters to the Editor. Thromb Haemost 73, 730-731 (1995). |
Antithrombin |
| 1. |
Ödegård O R et al. Heparin cofactor activity measured with an amidolytic method. Thromb Res 6, 287-294 (1975). |
| 2. |
National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3. |
| 3. |
Zucker S, Cathey M H, West B. Preparation of Quality control specimens for coagulation. Am J Clin Pathol 53, 924-927 (1970). |
| 4. |
Westgard J O, Barry P L. Cost-effective quality control: Managing the quality and productivity of analytical process. AACC press (1988). |
| 5. |
National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A2; vol. 11 No. 23. |
| 6. |
Tran T H et al. Influence of Heparin cofactor II (HCII) in the determination of Antithrombin III (AT). Thromb Res 40, 571-576 (1985). |
| 7. |
Tollefsen D M. Laboratory Diagnosis of Antithrombin and Heparin Cofactor II Deficiency. Seminars in Thromb Haemost 16,162-168 (1990). |
| 8. |
Andersson N-E et al. New chromogenic AT III activity kit which is insensitive to heparin cofactor II and designed for use on automated instruments.Thromb Haemost 65, 912 (1991). |
Factor VIII |
| 1. |
Van Dieijen G et al. The role of phospholipid and factor VIII in the activation of bovine factor X. J Biol Chem 256, 3433-3442 (1981). |
| 2. |
Mertens K et al: The role of factor VIII in the activation of blood coagulation factor X by activated factor IX. Thromb Haemost 54, 654-660 (1985). |
| 3. |
Rosén S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol 33, Suppl. 40 139-145 (1984). |
| 4. |
Rosén S et al: Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 54, 818-823 (1985). |
| 5. |
Lethagen S et al: Clinical application of the chromogenic assay of factor VIII in hemophilia A and different variants of von Willebrands disease. Scand J Haematol 37, 448-453 (1986). |
| 6. |
Tripodi A, Mannucci P M. Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay. Am J Clin Pathol 86, 341-343 (1986). |
| 7. |
Prowse C et al: Room temperature, microtray chromogenic assay of factor VIII:C. Vox Sang 50, 21-25 (1986). |
| 8. |
Carlebjörk G et al: A simple and accurate microplate assay for the determination of factor VIII activity. Thromb Res 47, 5-14 (1987). |
| 9. |
Koster T et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155 (1995). |
| 10. |
O'Donnell J et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 77, 825-828 (1997). |
| 11. |
National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3. |
| 12. |
National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A3; vol. 18 No. 20. Dec. 1998 |
Heparin |
| 1. |
TW Barrowcliffe et al. An International Standard for Low Molecular Weight Heparin. Thromb Haemostas 60, 1-7 (1988). |
| 2. |
H A Holm et al. The antithrombotic effect of Heparin in deep venous thrombosis. Relation to four heparin assays. Acta Med Scand 216, 287-293 (1984). |
| 3. |
HA Holm et al. Heparin assays and bleeding complications in deep venous throm-bosis with particular reference to retroperitonal bleeding. Thromb Haemostas 53, 278-281(1985). |
| 4. |
E Holmer et al. A new simple chromogenic assay for Heparin and Heparin-like anti-FXa activity in plasma. Thromb Haemostas 54, 29 (1985). |
| 5. |
AN Teien & M Lie. Evaluation of an amidolytic Heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 10, 399-410 (1977). |
| 6. |
H ten Cate et al. Automated amidolytic method for determinating Heparin, a heparinoid, and low-MR Heparin fragment, based on their anti-FXa activity. Clin Chem 30, 860-864 (1984). |
| 7. |
JJ van Putten et al. Heparin neutralisation during collection and processing of blood inhibited by pyrodoxal 5-phosphate. Haemostasis 14, 253-261 (1984). |
| 8. |
National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3. |
| 9. |
National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing andperformance of coagulation assays, NCCLS Document H21-A2; vol. 11 No. 23 |
Protein C |
| 1. |
STOCKNER K et al. Protein C activators in snake venoms. Behring Inst Mitt 79, 37-47 (1986). |
| 2. |
EXNER T and VAASJOKI R. Characterisation and some properties of the Protein C activator from Agkistrodon Contortrix venom. Thromb Haemost 59, 40-44 (1988). |
| 3. |
PABINGER I. Clinical relevance of Protein C. Blut 53, 63-75 (1986). |
| 4. |
VINAZZER H and PANGRAZ U. Protein C: Comparison of different assays in normal and abnormal plasma samples. Thromb Res 46, 1-8 (1987). |
| 5. |
WENDEL H P et al. Aprotinin in therapeutic doses inhibits chromogenic peptide substrate assays for Protein C. Thromb Res 74, 543-548 (1994). |
| 6. |
National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3. |
| 7. |
National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A2; vol. 11 No. 23. |
| 8. |
ZUCKER S, CATHEY M H, WEST B. Preparation of Quality control specimens for coagulation. Am J Clin Pathol 53, 924-927 (1970). |
| 9. |
WESTGARD J O, BARRY P L. Cost-effective quality control: Managing the quality and productivity of analytical process. AACC press (1988). |
